Transforming growth factor-beta in osteolytic breast cancer bone metastases
- PMID: 14600590
- DOI: 10.1097/01.blo.0000093055.96273.69
Transforming growth factor-beta in osteolytic breast cancer bone metastases
Abstract
Breast cancers frequently metastasize to the skeleton and cause bone destruction. Tumor cells secrete factors that stimulate osteoclasts. The consequent osteolytic resorption releases active factors from the bone matrix, in particular transforming growth factor-beta (TGF-beta). The released factors then stimulate tumor cell signaling, which causes breast cancer cells to make increased amounts of osteolytic factors, such as parathyroid hormone-related protein (PTHrP), interleukin-11 (IL-11), and vascular endothelial growth factor (VEGF). Therefore, tumor cell-bone cell interactions cause a vicious cycle in which tumor cells stimulate bone cells to cause bone destruction. As a consequence, the local microenvironment is enriched with factors that fuel tumor growth in bone. Transforming growth factor-beta is of particular importance because it increases breast cancer production of PTHrP. Parathyroid hormone-related protein then stimulates osteoblasts to express RANK (receptor activator of nuclear factor kappa B) ligand, which in turns enhances osteoclast formation and activity. Breast cancer osteolytic metastasis can be interrupted at four points in the vicious cycle: by neutralizing PTHrP biologic activity, by blocking the TGF-beta signaling pathway in the tumor cells, by inhibiting PTHrP gene transcription, and by inhibiting bone resorption.
Similar articles
-
Molecular mechanisms of tumor-bone interactions in osteolytic metastases.Crit Rev Eukaryot Gene Expr. 2000;10(2):159-78. Crit Rev Eukaryot Gene Expr. 2000. PMID: 11186331 Review.
-
Breast cancer metastasis to bone: it is not all about PTHrP.Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S39-45. doi: 10.1097/01.blo.0000093844.72468.f4. Clin Orthop Relat Res. 2003. PMID: 14600591 Review.
-
Mechanisms of osteolytic bone metastases in breast carcinoma.Cancer. 2003 Feb 1;97(3 Suppl):834-9. doi: 10.1002/cncr.11132. Cancer. 2003. PMID: 12548583 Review.
-
Tumor-bone cellular interactions in skeletal metastases.J Musculoskelet Neuronal Interact. 2004 Sep;4(3):308-18. J Musculoskelet Neuronal Interact. 2004. PMID: 15615499 Review.
-
Breast cancer bone metastasis and current small therapeutics.Cancer Metastasis Rev. 2006 Dec;25(4):635-44. doi: 10.1007/s10555-006-9035-x. Cancer Metastasis Rev. 2006. PMID: 17160709 Review.
Cited by
-
The Inhibitory Effects of Forsythia Koreana Extracts on the Metastatic Ability of Breast Cancer Cells and Bone Resorption by Osteoclasts.J Cancer Prev. 2016 Jun;21(2):88-94. doi: 10.15430/JCP.2016.21.2.88. Epub 2016 Jun 30. J Cancer Prev. 2016. PMID: 27390737 Free PMC article.
-
Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.PLoS One. 2012;7(11):e48871. doi: 10.1371/journal.pone.0048871. Epub 2012 Nov 16. PLoS One. 2012. PMID: 23173040 Free PMC article.
-
TGF-beta regulates the mechanical properties and composition of bone matrix.Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18813-8. doi: 10.1073/pnas.0507417102. Epub 2005 Dec 14. Proc Natl Acad Sci U S A. 2005. PMID: 16354837 Free PMC article.
-
The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate).J Bone Miner Res. 2017 Sep;32(9):1860-1869. doi: 10.1002/jbmr.3138. Epub 2017 Apr 21. J Bone Miner Res. 2017. PMID: 28337806 Free PMC article.
-
(2-Aminobenzothiazole)-Methyl-1,1-Bisphosphonic Acids: Targeting Matrix Metalloproteinase 13 Inhibition to the Bone.Pharmaceuticals (Basel). 2021 Jan 24;14(2):85. doi: 10.3390/ph14020085. Pharmaceuticals (Basel). 2021. PMID: 33498946 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
